Hormone replacement therapy: Clinical benefits and side-effects

Maturitas

Volumn 23, Issue SUPPL., 1996, Pages

  De Lignieres, Bruno ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Hormone replacement therapy; Plasma E2; Progesterone; Side effects

Indexed keywords

ESTRADIOL;

AMENORRHEA; ASTHENIA; DEPRESSION; DOSE RESPONSE; ESTRADIOL BLOOD LEVEL; FEMALE; HEADACHE; HORMONE SUBSTITUTION; HUMAN; MENSTRUAL CYCLE; MIGRAINE; OSTEOPOROSIS; PATIENT COMPLIANCE; REVIEW; SLEEP DISORDER; TRANSDERMAL DRUG ADMINISTRATION;

ANIMALIA;

EID: 0029785626     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-5122(96)01009-2     Document Type: Article

References (48)

1. Kanis JA. Treatment of osteoporosis in elderly women. Am J Med 1995; 98: 60-6S.
2. Psaty BM, Heckbert SR, Atkins D et al. A review of the association of estrogens and progestins with cardiovascular disease in postmenopausal women. Arch Intern Med 1993; 153: 1421-7.
3. Barrett-Connor E. Heart disease in women. Fertil Steril 1994; 62: 127-32S.
4. Larosa JC. Has HRT come of age? Lancet 1995; 345: 76-7.
5. Armamento-Villareal R, Civitelli R. Estrogen action on the bone mass of postmenopausal women is dependent on body mass and initial bone density. J Clin Endocrinol Metab 1995; 80: 776-82.
6. Holland EFN, Leather AT, Studd JWW. Increase in bone mass of older postmenopausal women with low mineral bone density after 1 year of percutaneous oestradiol implants. Br J Obstet Gynecol 1995; 102: 238-42.
7. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Ann Int Med 1995; 122: 9-16.
8. Coope J, Marsh J. Can we improve compliance with long-term HRT? Maturitas 1992; 15: 151-8.
9. Groeneveld FPMJ, Bareman FP, Barentsen R, Dokter HJ, Drogendijk AC, Hoes AW. Determinants of first prescription of hormone replacement therapy. A follow-up study among 1689 women aged 45-60 years. Maturitas 1995; 20: 81-9.
10. Wysowski DK, Golden L, Burke L. Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992. Obstet Gynecol 1995; 85: 6-10.
11. Stampfer MJ, Colditz GA, Willett WC et al. Postmenopausal estrogen therapy and cardiovascular disease. New Engl J Med 1991; 325: 756-62.
12. Ryan PJ, Harrison R, Blake GM, Fogelman I. Compliance with hormone replacement therapy after screening for post menopausal osteoporosis. Br J Obstet Gynaecol 1992; 99: 325-8.
13. Baird DT, Fraser IS. Blood production and ovarian secretion rates of estradiol-17b and estrone in women throughout the menstrual cycle. J Clin Endocrinol Metab 1974; 38: 1009-17.
14. Abraham GE, Odell WD, Swerdloff RS, Hopper K. Simultaneous radioimmunoassay of plasma FSH, LH, progesterone, 17-hydroxyprogesterone and estradiol-17β during the menstrual cycle. J Clin Endocrinol 1972; 34: 312-8.
15. Backstrom CT, McNeilly AS, Leask RM, Baird DT. Pulsatile secretion of LH, FSH, prolactin, oestradiol and progesterone during the human menstrual cycle. Clin Endocrinol 1982; 17: 29-42.
16. Godfrey KA, Aspillaga MO, Taylor A, Lind T. The relation of circulating progesterone and oestradiol concentrations to the onset of menstruation. Br J Obstet Gynaecol 1981; 88: 899-903.
17. Vermeulen A, Verdonck L. Sex hormone concentrations in post-menopausal women. Clin Endocrinol 1978; 9: 59-66.
18. Moos RH, Kopell BS, Melges FT et al. Fluctuations in symptoms and moods during the menstrual cycle. J Psychosom Res 1969; 13: 37-44.
19. Taylor JW. The timing of menstruation-related symptoms assessed by a daily symptom rating scale. Acta Psychiatr scand 1979; 60: 87-105.
20. Reid RL. Endogenous opiate peptides and prementrual syndrome. Sem Reprod Endocrinol 1987; 5: 191-7.
21. Fourestie V, De Lignieres B, Roudot-Thoraval F et al. Suicide attempts in hypo-oestrogenic phases of the menstrual cycle. Lancet 1986; 8520: 1357-60.
22. De Lignieres B, Vincens M, Mauvais-Jarvis P, Mas JL, Touboul PJ, Bousser MG. Prevention of menstrual migraine by percutaneous oestradiol. Br Med J 1986; 293: 1540.
23. Dennerstein L, Morse C, Burrows G, Oats J, Brown J, Smith M. Menstrual migraine: a double-blind trial of percutaneous estradiol. Gynecol Endocrinol 1988; 2: 113-20.
24. Steinglold KA, Laufer L, Chetkowski RJ et al. Treatment of hot flushes with transdermal estradiol administration. J Clin Endocrinol Metab 1985; 61: 627-32.
25. Dupont A, Dupont P, Cusan L et al. Comparative endocrinological and clinical effects of percutaneous estradiol and oral conjugated estrogens as replacement therapy in menopausal women. Maturitas 1991; 13: 297-311.
26. De Lignieres B, Vincens M. Differential effects of exogenous oestradiol and progesterone on mood in post-menopausal women: individual dose/effect relationship. Maturitas 1982; 4: 67-72.
27. De Lignieres B. Hormone replacement therapy compliance and individually adapted doses. 7th International Congress on Menopause, Stockholm, June 1993. Ed Plenum Press, 1993.
28. Devogelaer JP, Lecart C, Nagant de Deuschaisnes C. The effect of percutaneous estradiol on postmenopausal bone loss. 6th Ann Meeting Am Sovc Bone Mineral Res, Kansas City, September 9-13 1994. J Bone Miner Res 1994; 9: B398.
29. Field CS, Ory SJ, Wahner HW, Herrmann RR, Judd HL, Riggs BL. Preventive effects of transdermal 17b-estradiol on osteoporotic changes after surgical menopause: a 2-year placebo-controlled trial. Am J Obstet Gynecol 1993; 168: 114-21.
30. Lufkin EG, Wahner HW, O'Fallon WM et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117: 1-9.
31. De Lignieres B, Mauvais-Jarvis P. Hormonal dependence of benign breast disease, gynecomastia and breast cancer. In: Hollmann KH, Brux J de, Verley JM. New frontiers in mammary pathology. Ed Plenum Press, 1981: 287-308.
32. Ettinger B, Genant HK, Steiger P, Madvig P. Low-dosage micronized 17b-estradiol prevents bone loss in postmenopausal women. Am J Obstet Gynecol 1992; 166: 479-88.
33. Scott RT, Ross B, Anderson C, Archer DF. Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol. Obstet Gynecol 1991; 77: 758-64.
34. Kuhnz W, Gansau C, Mahler M. Pharmacokinetics of estradiol, free and total estrone, in young women following single intravenous and oral administration of 17b-estradiol. Arzneim-Forsch/Drug Res 1993; 43: 966-73.
35. Goldzieher JW, Dozier TS, De La Pena A. Plasma levels and pharmacokinetics of ethynyl estrogens in various populations. Contraception 1980; 21: 17-27.
36. Dusterberg B, Nishino Y. Pharmacokinetic and pharmacological features of oestradiol valerate. Maturitas 1982; 4: 315-24.
37. Longcope C, Gorbach S, Goldin B et al. The metabolism of estradiol: oral compared to intravenous administration. J Steroid Biochem 1985; 23: 1065-70.
38. The writing group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995; 273: 199-208.
39. Moyer DL, De Lignieres B, Driguez P, Pez JP. Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes. Fertil Steril 1993; 59: 992-7.
40. De Lignieres B, Moyer DL. Influence of sex hormones on hyperplasia/carcinoma risks. In: Lobo RA, ed. Treatment of the postmenopausal woman: basic and clinical aspects. New York: Raven Press, 1994; 373-83.
41. Gillet JY, Andre G, Faguer B et al. Induction of amenorrhea during hormone replacement therapy: optimal micronized progesterone dose. A multicenter study. Maturitas 1994; 19: 103-15.
42. De Lignieres B, Dennerstein L, Backstrom T. Influence of route of administration on progesterone metabolism. Maturitas 1995; 21: 251-7.
43. Madjar H, Vetter M, Prompeler H, Breckwoldt M, Pfleiderer A. Doppler measurement of breast vascularity in women under pharmacologic treatment of benign breast disease. J Reprod Med 1993; 38: 935-40.
44. Colditz GA, Hankinson SE, Hunter DJ et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. New Engl J Med 1995; 332: 1589-93.
45. Chang KJ, Lee TTY, Linares-Cruz G et al. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril 1995; 63: 785-91.
46. Risch HA, Howe GR. Menopausal hormone usage and breast cancer in Saskatchewan: a record-linkage cohort study. Am J Epidemiol 1994; 139: 670-83.
47. Stanford JL, Weiss NS, Voigt LF et al. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995; 274: 137-42.
48. Bonnier P, Romain S, Giacalone PL, Laffargue F, Martin PM, Piana L. Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 1995; 85: 11-7.